JPMorgan analyst Benjamin Rossi assumed coverage of Tenet Healthcare (THC) with an Overweight rating and $175 price target The firm believes favorable trends across sales and expenses for managed care companies should allow for margin expansion in 2025, but considers the setup into 2026 to be more bearish, saying potential volume rollover and regulatory uncertainty following the November elections present an “imperfect storm” of payer mix headwinds and a negative overhang on go-forward sentiment for the hospitals.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Netflix, MongoDB downgraded: Wall Street’s top analyst calls
- Tenet Healthcare downgraded to Neutral from Buy at Goldman Sachs
- Block, Five Below downgraded: Wall Street’s top analyst calls
- Tenet Healthcare downgraded to Equal Weight from Overweight at Wells Fargo
- Amazon invests $4B more in Anthropic, Gap reports Q3 beat: Morning Buzz